Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Evaluation of the Fully Closed Loop Omnipod® System in Type 2 Diabetes

NCT: NCT07521475 · NOT_YET_RECRUITING

NCT IDNCT07521475
StatusNOT_YET_RECRUITING
Start Date2026-04-20
Completion2027-09-23

Brief Summary

A multi-center, 26-week randomized controlled trial (RCT) to evaluate the safety and efficacy of the fully closed loop Omnipod M System in adults with type 2 diabetes using basal/bolus insulin therapy or basal-only insulin therapy, with the primary endpoint after 15 weeks and secondary analysis at 26 weeks; followed by an extension phase after completion of the 26-week trial where the Intervention group will continue to use Omnipod M and the Control group will crossover to use Omnipod M for 26 weeks

Frequently Asked Questions

What is Evaluation of the Fully Closed Loop Omnipod® System in Type 2 Diabetes?

Evaluation of the Fully Closed Loop Omnipod® System in Type 2 Diabetes is a clinical trial registered under NCT07521475. Current status: NOT_YET_RECRUITING.

What is the status of NCT07521475?

The current status of NCT07521475 (Evaluation of the Fully Closed Loop Omnipod® System in Type 2 Diabetes) is: NOT_YET_RECRUITING.

When did Evaluation of the Fully Closed Loop Omnipod® System in Type 2 Diabetes start?

Evaluation of the Fully Closed Loop Omnipod® System in Type 2 Diabetes started on 2026-04-20.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.